Free Treatment Of Children With Rare Diseases, Delhi HC Seeks AIIMS Response
- byDoctor News Daily Team
- 06 August, 2025
- 0 Comments
- 0 Mins
 
                            
                                    New Delhi: Taking cognizance of the pleas concerning the free treatment of children with rare diseases like Duchenne Muscular Dystrophy (DMD), Hunter's Syndrome, etc., the Delhi High Court on Monday seeks the response of the premier health institute, All India Institute of Medical Science (AIIMS) New Delhi in the matter.
On December 22, last year, a single-judge bench of Justice Prathiba M. Singh had directed the Centre to release Rs 5.35 crore immediately so as to enable clinical trials for medicines that can help treat such rare diseases.
Also Read:Delhi HC Directs AIIMS: To examine medical records of Patients before commencing treatment for Duchenne Muscular Dystrophy (DMD)
"The court believes that the development of treatment for children with rare diseases should be considered a 'Nationally Important Project' due to the enormity of the issues confronting these children," she had said.
Dr Kanika from AIIMS apprised the court that the tender has been given and the amount will be released in September 2023.
At this, Justice Singh remarked: "This is just shocking, I can't believe AIIMS is behaving like this."
The court then directed the doctor to be present in court on the next date of the hearing and listed the matter for review after 10 days.
The petitioner, who sought directions to provide the children suffering from rare diseases like DMD and Hunter's Syndrome with free treatment, had earlier informed Justice Singh that a Memorandum of Understanding (MoU) with respect to the indigenous development of therapies for rare diseases was signed between Biotechnology Industry Research Assistance Council and Hanugen Therapeutics Private Ltd in January 2021.
As per the MoU, a multicentric study for therapeutic evaluation with respect to DMD patients will be conducted by Hanugen.
The HC, however, had noted that as per the agreement, 50 percent of the study would be funded by the Centre while the remaining will come from the company.
Also Read:Delhi HC directs centre to release over Rs 5 Cr to fund clinical trials for rare diseases
                                
    Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
    The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
    Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
    If you come across any inconsistencies, please reach out to us at 
    admin@doctornewsdaily.com.
    We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
    By using this website, you agree to our 
    Terms of Use, 
    Privacy Policy, and 
    Advertisement Policy.
    For further details, please review our 
    Full Disclaimer.
Tags:
Recent News
Merck Keytruda wins European Commission nod for lo...
- 30 October, 2025
UP NEET 2025 round 3 allotment results postponed
- 30 October, 2025
Achin Gupta to succeed Umang Vohra as Cipla MD, GC...
- 30 October, 2025
Mumbai shocker: KEM Hospital doctor stabbed by col...
- 30 October, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
 
                     
                    
0 Comments
Post a comment
No comments yet. Be the first to comment!